{'fraction_non_alphanumeric': 0.043233082706766915, 'fraction_numerical': 0.009398496240601503, 'mean_word_length': 6.0131578947368425, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Tablets or oral suspension for posaconazole in lung transplant recipients? Consequences for trough concentrations of tacrolimus and everolimus

A new formulation of posaconazole (PCZ), delayed‐release tablets (PCZ‐tab), increases PCZ bioavailability and plasma trough concentrations (Cmin) over those achieved with an oral suspension (PCZ‐susp). PCZ is an inhibitor of cytochrome P450 3A4 and P‐glycoprotein. We therefore investigated the impact of PCZ‐tab treatment on blood Cmin and doses of tacrolimus (TAC) and everolimus (EVR).